In first look at mRNA protein replacement, Moderna touts early signals of promise for rare metabolic therapy

Lei Lei Wu

News Reporter

LOS ANGELES — Moderna presented early data on its mRNA treatment for propionic acidemia (PA), a rare metabolic disease where people can’t break down certain …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

In first look at mRNA protein replacement, Moderna touts early signals of promise for rare metabolic therapy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

In first look at mR­NA pro­tein re­place­ment, Mod­er­na touts ear­ly sig­nals of promise for rare meta­bol­ic ther­a­py

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

In first look at mRNA protein replacement, Moderna touts early signals of promise for rare metabolic therapy